Shah, A., Tosh, J. C., Ambavane, A., Nikolaou, A., Hogea, C., Samyshkin, Y., . . . Wang, F. (2021). Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States. ClinicoEconomics and outcomes research : CEOR, 13, p. 789. doi:10.2147/CEOR.S310619
Chicago ZitierstilShah, Anshul, Jonathan C. Tosh, Apoorva Ambavane, Andreas Nikolaou, Cosmina Hogea, Yevgeniy Samyshkin, Boris Gorsh, Eric M. Maiese, and Feng Wang. "Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma in the United States." ClinicoEconomics and Outcomes Research : CEOR 13 (2021): 789.
MLA ZitierstilShah, Anshul, et al. "Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma in the United States." ClinicoEconomics and Outcomes Research : CEOR 13 (2021): 789.